Patient characteristics
| Characteristic | Pazopanib (N = 221) | Sunitinib (N = 232) |
|---|---|---|
| Median age, y (range) | 62 (30–86) | 62 (33–86) |
| Sex, n (%) | ||
| Male | 158 (71) | 178 (77) |
| Female | 63 (29) | 54 (23) |
| Prior nephrectomy, n (%) | 191 (86) | 205 (88) |
| KPS, n (%) | ||
| 70 or 80 | 57 (26) | 60 (26) |
| 90 or 100 | 164 (74) | 169 (74) |
| LDH, n (%) | ||
| >1.5× ULN | 17 (8) | 11 (5) |
| ≤1.5× ULN | 204 (92) | 214 (95) |
| Metastatic sites at baseline, n (%) | ||
| ≤2 | 151 (68) | 152 (65) |
| >2 | 70 (32) | 80 (34) |
| MSKCC risk category, n (%) | ||
| Favorable | 64 (29) | 55 (24) |
| Intermediate | 127 (57) | 142 (61) |
| Poor | 26 (12) | 24 (10) |
| Unknown | 4 (2) | 11 (5) |
Abbreviation: ULN, upper limit of the normal range.